Magtein study explores magnesium L-threonate in collegiate athletes

A UCLA study is investigating whether magnesium L-threonate can support sleep, recovery and physical performance in college athletes

ThreoTech has announced preliminary findings from a UCLA study investigating magnesium L-threonate in collegiate athletes, with the research examining potential effects on sleep, recovery and physical performance.

The randomised, placebo-controlled study, led by Dr Jeremy Swisher, a UCLA sports medicine physician, evaluated Magtein, ThreoTech’s branded form of magnesium L-threonate, in college athletes during a period of four weeks.

The findings were first presented as a poster at the American Medical Society for Sports Medicine (AMSSM) Annual Meeting in April 2026.

The firm said it expects to publish full results in a peer-reviewed journal later this year.


The research is part of a broader clinical programme investigating magnesium L-threonate, with previous human studies examining outcomes including cognition and sleep.1,2

A 2024 randomised controlled trial, for example, reported improvements in sleep quality and daytime functioning among adults with self-reported sleep problems.

Threotech added that, to date, five peer-reviewed, randomised, double-blind, placebo-controlled human trials on Magtein have already been published across three countries: the United States, China and Australia. 


The UCLA study is listed as investigating magnesium L-threonate in relation to sleep, recovery, athletic performance and heart rate variability in healthy adults aged 18-35.3

The trial was initiated in October 2025.

Magtein enters the sports arena

For ThreoTech, the research also represents an expansion into sports nutrition applications for Magtein.

The company is the exclusive global ingredient supplier and patent licensee for the branded magnesium L-threonate ingredient, which it describes as a research-focused ingredient for brain health.

Magtein has also received EU novel food and UK authorisation, widening its potential use in supplement formulations in these markets.

ThreoTech will discuss the UCLA research during a breakfast briefing at SupplySide Global on 28 October and will exhibit at Booth 5652.

Dr Rafea Naffa, Director of R&D at ThreoTech, said: “We’ve always been interested in Magtein’s potential in sports nutrition and we're delighted that new research is now specifically examining Magtein's benefits in athletes."

References: 

  1. https://www.sciencedirect.com/science/article/pii/S2590142724000193
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC11381753/
  3. https://ucla.clinicaltrials.researcherprofiles.org/trial/NCT07015047

You may also like